Calcitonin is a polypeptide hormone that inhibits calcium resorption from bones by an action on osteoclasts. It is indicated for the treatment of postmenopausal osteoporosis, Paget’s disease, and bone metastasis. Currently, calcitonin from salmon species is commercially available in the form of injection and intranasal spray
(Miacalcin®). Data on the bioavailability of Miacalcin® shows great variability with an average bioavailability of 3% as compared to injection (Hinchcliffe et al., 2005). The systemic delivery of calcitonin via the lungs is as a promising alternative (Patton, 2000).
In contrast to other mucosal barriers, the pulmonary epithelium is more permeable to macromolecules and has lower enzymatic activity (Patton, 1996). Yet, certain
(Miacalcin®). Data on the bioavailability of Miacalcin® shows great variability with an average bioavailability of 3% as compared to injection (Hinchcliffe et al., 2005). The systemic delivery of calcitonin via the lungs is as a promising alternative (Patton, 2000).
In contrast to other mucosal barriers, the pulmonary epithelium is more permeable to macromolecules and has lower enzymatic activity (Patton, 1996). Yet, certain